Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (161 d 06:41 ago) – Posting: # 24336
Views: 2,093

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?


Edit: Category changed; see also this post #1[Helmut]

Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
44 visitors (0 registered, 44 guests [including 10 identified bots]).
Forum time: 07:38 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5